Literature DB >> 1479561

Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?

P Veng-Pedersen1, N B Modi.   

Abstract

Neural networks (NN) are computational systems implemented in software or hardware that attempt to simulate the neurological processing abilities of biological systems, in particular the brain. Computational NN are classified as parallel distributed processing systems that for many tasks are recognized to have superior processing capability to the classical sequential Von Neuman computer model. NN are recognized mainly in terms of their adaptive learning and self-organization features and their nonlinear processing capability and are considered most suitable to deal with complex multivariate systems that are poorly understood and difficult to model by classical inductive, logically structured modeling techniques. A NN is applied to demonstrate one of the potentially many applications of NN for modeling complex kinetic systems. The NN was used to predict the effect of alfentanil on the heart rate resulting from a complex infusion scheme applied to six rabbits. Drug input-drug effect data resulting from a repeated, triple infusion rate scheme lasting from 30 to 180 min was used to train the NN to recognize and emulate the input-effect behavior of the system. With the NN memory fixed from the 30- to 180-min learning phase the NN was then tested for its ability to predict the effect resulting from a multiple infusion rate scheme applied in the subsequent 180 to 300 min of the experiment. The NN's ability to emulate the system (30-180 min) was excellent and its predictive extrapolation capability (180-300 min) was very good (mean relative prediction accuracy of 78%). The NN was best in predicting the higher intensity effect and was able to identify and predict an overshoot phenomenon likely caused by a withdrawal effect from acute tolerance. Current modeling philosophy and practice is discussed on the basis of the alternative offered by NN in the modeling of complex kinetic systems. In modeling such systems it is questioned whether traditional modeling practice that insists on structure relevance and conceptually pleasing structures has any practical advantages over the empirical NN approach that largely ignores structure relevance but concentrates on the emulation of the behavior of the kinetic system. The traditional searching for appropriate models of complex kinetic systems is a painstakingly slow process. In contrast, the search for empirical models using NN will continue to improve, limited only by technological advances supporting the very promising NN developments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479561     DOI: 10.1007/bf01062465

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  5 in total

1.  Application of neural computing in pharmaceutical product development.

Authors:  A S Hussain; X Q Yu; R D Johnson
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

Review 2.  Computational neuroscience.

Authors:  T J Sejnowski; C Koch; P S Churchland
Journal:  Science       Date:  1988-09-09       Impact factor: 47.728

3.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

4.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

5.  Numerical deconvolution by least squares: use of prescribed input functions.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1978-06
  5 in total
  7 in total

Review 1.  Nonlinearity in the epidemiology of complex health and disease processes.

Authors:  P Philippe; O Mansi
Journal:  Theor Med Bioeth       Date:  1998-12

Review 2.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

3.  Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks.

Authors:  J Opara; S Primozic; P Cvelbar
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

4.  Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates.

Authors:  I S Nestorov; S T Hadjitodorov; I Petrov; M Rowland
Journal:  AAPS PharmSci       Date:  1999

Review 5.  The backpropagation neural network--a Bayesian classifier. Introduction and applicability to pharmacokinetics.

Authors:  R J Erb
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 6.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

7.  Neural network predicted peak and trough gentamicin concentrations.

Authors:  M E Brier; J M Zurada; G R Aronoff
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.